Prof Paul Workman

Professor Paul Workman FRS FMedSci is Chief Executive and President of The Institute of Cancer Research, London, and he is also Harrap Professor of Pharmacology and Therapeutics at the ICR. From 1997 to January 2016, Paul was Director of the Cancer Research UK Cancer Therapeutics Unit at the ICR – the world’s largest non-profit cancer drug discovery group. Before joining ICR, Paul spent 4 years leading cancer research at AstraZeneca and prior to that worked at Glasgow, Stanford and Cambridge Universities. He was a scientific founder of Piramed Pharma (acquired by Roche) and Chroma Therapeutics. In addition to running his own lab, Paul guides strategic developments in the field of basic, translational and clinical cancer research. Paul also talks, writes and blogs about cancer research and treatment, and also about the drug discovery ecosystem. He is also a member of a number of boards and committees, both non-profit and commercial.